Shire PLC (LON:SHP) shares traded down 0% during trading on Tuesday . The company traded as low as GBX 3,880.50 ($51.89) and last traded at GBX 3,880.50 ($51.89). 0 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 2,570,000 shares. The stock had previously closed at GBX 3,880.50 ($51.89).
A number of research firms have commented on SHP. Liberum Capital downgraded Shire to a “hold” rating and reduced their target price for the stock from GBX 4,200 ($56.16) to GBX 4,100 ($54.82) in a report on Wednesday, December 20th. Deutsche Bank reaffirmed a “buy” rating on shares of Shire in a report on Monday, December 11th. Citigroup reaffirmed a “buy” rating and set a GBX 5,500 ($73.54) target price on shares of Shire in a report on Friday, December 8th. Morgan Stanley reaffirmed an “overweight” rating and set a GBX 5,700 ($76.21) target price on shares of Shire in a report on Friday, December 1st. Finally, Societe Generale increased their target price on Shire from GBX 7,500 ($100.28) to GBX 8,000 ($106.97) and gave the stock a “buy” rating in a report on Wednesday, November 29th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of GBX 5,272.22 ($70.49).
The company has a market cap of $35,280.00 and a PE ratio of 2,951.89.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Week Herald and is owned by of Week Herald. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://weekherald.com/2017/12/28/shire-shp-stock-price-down-0.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.